INSM
INSMED Inc
NASDAQ · Healthcare · Biotechnology · US
$111.59
+15.06%Year over year
Reported trailing growth
- Revenue
- +185.8%
- EBITDA
- +17.8%
- EBIT
- +18.6%
- EPS
- +28.0%
- Free cash flow
- +3.6%
- Operating cash flow
- +7.8%
Forward estimates
Based on analyst estimates
- Revenue
- +134.4%
- EBITDA
- +117.2%
- EPS
- +98.9%
Three-year CAGR
- Revenue
- +35.2%
- EBITDA
- -43.1%
- EBIT
- -34.0%
- Net income
- -39.7%
- EPS
- -15.1%
- Free cash flow
- -37.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026